DERIVATIVE FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

12 Months Ended

Jun. 30, 2023

		Initial Valuations (on new derivative instruments entered into during the year ended June 30, 2023)
Volatility		228.29 – 256.02%
Expected Remaining Term (in years)		0.22 – 0.28
Risk Free Interest Rate		3.13 – 4.42%
Expected dividend yield		None

	Balance at June 30, 2023		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
			(Level 1)		(Level 2)		(Level 3)
Embedded conversion option liabilities	$	423,209	$	—	$	—	$	423,209
Total	$	423,209	$	—	$	—	$	423,209

PROPANC BIOPHARMA, INC. AND SUBSIDIARY

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

June 30, 2023 and 2022

The following tables summarize the Company’s financial assets and liabilities measured at fair value on a recurring basis as of June 30, 2022:

	Balance at June 30, 2022		Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
			(Level 1)		(Level 2)		(Level 3)
Embedded conversion option liabilities	$	151,262	$	—	$	—	$	151,262
Total	$	151,262	$	—	$	—	$	151,262

The following is a roll forward for the years ended June 30, 2023 and 2022 of the fair value liability of price adjustable derivative instruments:

	Fair Value of
	Liability for
	Derivative
	Instruments
Balance at June 30, 2021	$	54,220
Initial fair value of embedded conversion option derivative liability recorded as debt discount		-
Gain on debt extinguishment		(2,069	)
Change in fair value included in statements of operations		99,111
Balance at June 30, 2022		151,262
Beginning balance		151,262
Initial fair value of embedded conversion option derivative liability recorded as debt discount		93,668
Gain on debt extinguishment		(352,051	)
Change in fair value included in statements of operations		530,330
Balance at June 30, 2023	$	423,209
Ending balance	$	423,209